NCT06559722View on ClinicalTrials.gov

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

510

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions

Type 2 Diabetes

Interventions

DRUG

Insulin Degludec/liraglutide Injection

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.

DRUG

XULTOPHY®

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.

All Listed Sponsors

lead

Tonghua Dongbao Pharmaceutical Co.,Ltd

INDUSTRY

NCT06559722 - A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter